Answers are grounded in this paper and cite their sources.
Review discusses synthesis of 5-arylidene-imidazolones, their anticholinesterase activity, indicating drug development potential for Alzheimer's disease.
This review article summarizes literature data on the use of various silylating agents (trimethylchlorosilane, dimethyldichlorosilane, 1,1,1,3,3,3-hexamethyldisilazane, bis-trimethylacetamide, N-trimethylsilylimidazole) in the synthesis of 5-arylidene-4-imidazolones from unsaturated 5(4H)-oxazolones and amides of N-acyl-α,β-dehydroamino acids. The synthesis approaches are discussed, particularly starting from unsaturated 5(4H)-oxazolones (one-pot method), the formation of by-products depending on the silylating agent used and reaction conditions, as well as the possible reaction mechanism. In addition, data concerning the anticholinesterase properties of 5-arylidene-3,5-dihydro-5(H)-imidazol-4-ones, and the results of docking these ligands with both acetylcholinesterase and butyrylcholinesterase are presented. The feasibility of using the 4-imidazolone scaffold in the development of drugs for the treatment of Alzheimer’s disease is demonstrated.
No takes yet. Share an insight, caveat, or question.
Topuzyan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: